-
Mashup Score: 61CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement - a multicenter experience. - 5 day(s) ago
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 58CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement - a multicenter experience. - 7 day(s) ago
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome - 2 month(s) ago
Survival in fit adults with AML has steadily improve d over the past decade; thanks, largely, to the advent of new drugs targeting molecular pathways pivotal to disease pathogenesis. 1, 2 Despite this notable progress, allogeneic stem cell transplantation (allo-SCT), a technique pioneered more than half a century ago, still remains the most potent antileukemic modality in high-risk AML, and advances in transplant technology now allow the delivery of a potentially curative graft-versus-leukemia (GVL)
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome - 2 month(s) ago
Survival in fit adults with AML has steadily improve d over the past decade; thanks, largely, to the advent of new drugs targeting molecular pathways pivotal to disease pathogenesis. 1, 2 Despite this notable progress, allogeneic stem cell transplantation (allo-SCT), a technique pioneered more than half a century ago, still remains the most potent antileukemic modality in high-risk AML, and advances in transplant technology now allow the delivery of a potentially curative graft-versus-leukemia (GVL)
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? - PubMed - 2 month(s) ago
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@BMTCTN @DrStevenDevine @MartinTallman @bmtdata 4/x many questioned the ethics of this trial after Sormain results, but we discussed the ethic of protocol in a 2019 @JCO_ASCO position statement. Thank u to @charliecraddock for publishing that editorial that proved vital for completion of this study https://t.co/jIW4SIHFI6
-
-
Mashup Score: 5Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014 - 2 month(s) ago
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-ri …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study - PubMed - 2 month(s) ago
ClinicalTrials.gov identifier: NCT01166009.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20
CD19-targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is a CD19-targeting antibody-drug conjugate indicated for R/R DLBCL after at least two systemic treatments. CD19 expression wa …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma - 3 month(s) ago
Despite the multiple therapies currently available for patients with relapsed B cell malignancies, including those targeting CD19, outcomes are still poor for nonresponders. Approximately one-third of patients with diffuse large B cell lymphoma (DLBCL) will develop relapsed/refractory (R/R) disease to initial therapy.1 Second-line intensive chemotherapy for R/R disease is either infeasible or ineffective in approximately 70% of R/R DLBCL patients. Other aggressive CD20+ B cell non-Hodgkin lymphomas (NHLs) with similar treatment challenges include primary mediastinal B cell lymphoma, grade 3b follicular lymphoma (FL), transformed histology FL, and mantle cell lymphoma.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
CAR T-cell Therapy in Mantle cell with sCNS Involvement. Active disease PFS only 25%, without active disease about 33%. Perhaps needs post CT maintenance? @mshadman @gulrayzahmed @awandoc @timfenske @MadihaIqbal13 @MKD_BMT @MCWCancerCenter #lymsm #CART https://t.co/fjBAz6IrGo